Useful for measuring tauro- and glycol-conjugated and unconjugated bile acid constituents in serum, for monitoring patients receiving bile acid therapy (such as cholic acid, deoxycholic acid, or ursodeoxycholic acid), for aiding in the evaluation of liver function, and for the evaluation of liver function changes before the formation of more advanced clinical signs of illness such as icterus. Also useful for determining hepatic dysfunction as a result of chemical and environmental injury, for indicating hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment, and for indicating intrahepatic cholestasis of pregnancy (ICP).
Allow SST tube to clot for at least 15 minutes post-draw. Centrifuge unopened collection tube(s) for 15 minutes to separate serum from red cells. Submit unopened collection tube(s).
FDA-approved cancer-associated antigen (CA 27.29) for serial testing in women with prior stage II or III breast cancer who are clinically free of disease. Useful for predicting early recurrence of disease in women with treated carcinoma of the breast, and to indicate that additional tests or procedures should be performed to confirm recurrence of breast cancer
Allow SST tube to clot for at least 15 minutes post-draw. As soon as possible, centrifuge unopened collection tube(s) for 15 minutes to separate serum from red cells, aliquot into a plastic transport vial, and freeze.
Pour Off Within 2 HR. CRITICAL FROZEN.
FREEZE (90 Days) CRITICAL
Biomira Truquant BR, Breast Cancer Tumor Markers, Breast Carcinoma, Cancer Antigen 27.29 (CA 27.29), MAM 6, Milk Mucin, CA2729